Navigation Links
Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
Date:1/27/2011

BOSTON, Jan. 27, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company generated revenues during the three months ended December 31, 2010 in the amount of $90,005. The revenue for the three month period is a result of instrument sales to over fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos looks towards continued growth in 2011 through new product development, new product sales and the completion of the requirements for the Company's ISO 13485 quality management system (QMS) initiative. The ISO QMS initiative is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union. Solos recently announced the approval of its 2011 recapitalization plan, which allows greater flexibility to utilize the assets of the Company to raise the necessary capital to achieve the aforementioned goals.

"As an innovative HealthCare instrument company, Solos continues to position itself to take advantage of the ever increasing demand of the medical industry," stated Bob Segersten, President of Solos Endoscopy, Inc. "Our portfolio is centered on instruments like the MammoView Breast Endoscopy System that are designed to support a wide range of options from screening and diagnosis, to treatment and management of medical conditions."

The Company expects to post its full unaudited financial results for the three months ended December 31, 2010 on the OTC Markets Group website within in the next sixty days.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. Trends toward Strong Continued Growth in 2011
2. Solos Endoscopy, Inc. Announces Recapitalization Plan for 2011
3. Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010
4. Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting
5. Solos Endoscopy, Inc. to Hold Annual Shareholder Meeting September 28, 2010
6. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
7. Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
8. Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth
9. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
10. Solos Endoscopy, Inc. Set To Develop European Union Conforming CE Mark Technical File
11. Solos Endoscopy, Inc. Set To Develop New Polymer Dilator For MammoView(TM) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... New York , March 28, 2017 ... a largely consolidated vendor landscape, with the top three ... Agilent Technologies accounting for a significant 49% of the ... a recent report. The vendor landscape is intensely competitive ... share in the overall market. These factors have restricted ...
(Date:3/28/2017)... and TEL AVIV, Israel , March 28, ... in Israel . This new business entity, Emosis ... mostly dedicated to research and development of novel assays complementing the ... also, when relevant, locally support commercialization and sales development of Emosis ... This strategic ...
(Date:3/28/2017)... ROCKVILLE, Md. , March 28, 2017 /PRNewswire/ ... dedicated to innovative therapeutics addressing cancer and other ... at the American Association for Cancer Research annual ... April 3 is entitled "Evaluation of ENMD-2076 ... and the second poster to be presented ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management Association (RBMA) ... as its new executive director. Mr. Still was selected through a careful months-long search ... as he is known to our members, has been a part of building the ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists ... to quality care can be limited while the desire to conquer breakouts and eliminate ... acne care for every customer online, today released its inaugural survey on the State ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in mind, ... March. , The seed processing plant opened in Marshallville in 2006, and a bagging ... office allows opportunity for transition of Patten Seed operations to the Middle Georgia location ...
Breaking Medicine News(10 mins):